A number of stocks jumped in the morning session after a Federal judge ruled that advertising giant Google (owned by Alphabet) monopolized online advertising technology. The affected technologies were the publisher ad servers and exchanges. These platforms are central to how digital ads are bought, sold, and placed across the internet, and they have been major revenue drivers for Alphabet. The decision raised the possibility that Alphabet could be forced to divest these assets, potentially weakening its control over digital ad infrastructure and creating new growth opportunities for independent ad tech firms.
Over the last six months, Avnet shares have sunk to $45.83, producing a disappointing 16.4% loss - worse than the S&P 500’s 6.9% drop. This might have investors contemplating their next move.
Jamf’s stock price has taken a beating over the past six months, shedding 31.9% of its value and falling to $11.55 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how PubMatic (NASDAQ:PUBM) and the rest of the advertising software stocks fared in Q4.
RBLX stock spiked after the company announced a partnership with Alphabet to launch programmatic advertising, but both fundamental and technical risks remain
Let’s dig into the relative performance of Upland (NASDAQ:UPLD) and its peers as we unravel the now-completed Q4 sales and marketing software earnings season.
What a brutal six months it’s been for Avery Dennison. The stock has dropped 24.1% and now trades at $165.51, rattling many shareholders. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Although the S&P 500 is down 9.9% over the past six months, Universal Health Services’s stock price has fallen further to $178.59, losing shareholders 16.7% of their capital. This may have investors wondering how to approach the situation.
Zimmer Biomet has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $101.84. However, the stock is beating the S&P 500’s 9.8% decline during that period.
Clarus’s stock price has taken a beating over the past six months, shedding 24.8% of its value and falling to a new 52-week low of $3.30 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Shareholders of B&G Foods would probably like to forget the past six months even happened. The stock dropped 23.6% and now trades at $5.99. This might have investors contemplating their next move.
Integer Holdings trades at $113.57 per share and has stayed right on track with the overall market, losing 11.4% over the last six months while the S&P 500 is down 7.7%. This may have investors wondering how to approach the situation.
Shareholders of AMC Entertainment would probably like to forget the past six months even happened. The stock dropped 34.6% and now trades at $2.66. This was partly due to its softer quarterly results and might have investors contemplating their next move.
